September 2018
Volume 4, Issue 11
This issue features a look at research misconduct, a debate about whether chronic lymphocytic leukemia is curable, and more.
Table of Contents
September 2018 Issue
My Twitter Journey
My journey to Twitter was not my idea. A few years ago, the chairman of the Cleveland Clinic Taussig Cancer Institute, Brian Bolwell, MD...
Notes From the Field
Readers responded to two of our recent articles that offered a candid look into the daily lives of physician-researchers and advice for thriving as...
Summertime Blues
At the time of writing this column, the calendar has just turned to August and another July has come and gone. There’s plenty of...
September 2018 Issue
NIH Awards $24 Million to UT Health San Antonio, and more
Remembering Michael C. Lill (1959-2018)
Michael C. Lill, MD, passed away on June 19, 2018, after a long battle with cancer. Dr. Lill was born...
Start Planning Now for the 60th ASH Annual Meeting and Exposition, and more
Start Planning Now for the 60th ASH Annual Meeting and Exposition
The preliminary program for the 2018 ASH annual meeting is now available online. The...
September 2018 Issue
The Code of Misconduct
Scientific misconduct is more than falsification, fabrication, and plagiarism – and harder to identify.
In 1998, Andrew Wakefield, MD, and co-authors investigated a cohort of...
Pulling Back the Curtain: Robert Glassman, MD
In this edition, Robert Glassman, MD, talks about the “risky yet refreshing” transition from clinical practice to the financial world and explains how grand...
Is Chronic Lymphocytic Leukemia Curable With Newer Agents?
Chronic lymphocytic leukemia (CLL) has long been considered an incurable disease. The goal of traditional frontline treatments is to minimize disease burden and allow...
September 2018 Issue
Next Steps After TKIs for Patient With Chronic-Phase CML?
Here’s how readers responded to a You Make the Call question about the next steps after TKIs for patient with chronic-phase chronic myeloid leukemia.
Disclaimer:...
How I Treat In Brief: Managing Disseminated Intravascular Coagulation
Recently, Marcel Levi, MD, and Marie Scully, MD, wrote about their strategies for the management of patients with disseminated intravascular coagulation (DIC). Below, we...
Next Steps After TKIs for Patient With Chronic-Phase CML?
This month, Michael Deininger, MD, PhD, discusses treatment for a patient with chronic-phase chronic myeloid leukemia (CML) whose BCR/ABL transcript levels are rising.
And don't...
September 2018 Issue
Can Cytarabine Prevent Progression to Myeloid Leukemia in Children With Down Syndrome and Transient...
In pediatric patients with Down syndrome (DS) and transient myeloproliferative disorder (TMD), treatment with low-dose cytarabine lowered early mortality risk, compared with historical controls,...
Insurance Status Contributes to Survival Disparities in Follicular Lymphoma
Patients with follicular lymphoma (FL) who have private health-care insurance live longer than uninsured patients or those who are enrolled in Medicare, according to...
No Benefit, but Excess Toxicity, With Rivaroxaban for Patients With High-Risk Antiphospholipid Syndrome
Rivaroxaban and other direct oral anticoagulants are used as an alternative to warfarin for the prevention of thromboembolism, but data do not support routine...
FDA Approves Ivosidenib for Previously Treated, IDH1-Mutated AML
The FDA approved ivosidenib, a small-molecule IDH1 inhibitor, for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) and an...
Freeze-Dried Plasma Approved for Battlefield Treatment
Under an emergency-use authorization, the FDA approved the use of freeze-dried plasma by the U.S. military. The authorization, requested by the U.S. Department of...
Medical Community Reacts to the Supreme Court’s Travel Ban Ruling
On June 26, 2018, the U.S. Supreme Court voted to uphold President Donald Trump’s travel ban, restricting immigration from seven “high-risk” countries (Syria, Iran,...
FDA Issues New Guidance for Patient-Centered Drug Development
The U.S. Food and Drug Administration (FDA) recently announced an initiative to better integrate the patient experience into clinical trials. The agency has released...
Researchers Identify Cancer Gene Mutations Associated with Poor Outcomes in CML
Despite the good outcomes experienced by most patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs), a subset do not...
Ibrutinib-Rituximab Combo Granted Priority Review
The FDA granted priority-review designation to the combination of ibrutinib and rituximab for the treatment of Waldenström macroglobulinemia (WM). The Bruton tyrosine kinase inhibitor...
Study Reveals Platelet Counts Decrease for All Women During Pregnancy
Gestational thrombocytopenia (defined as a platelet count <150,000/mm3 during uncomplicated pregnancy) has been recognized for more than 25 years, but the course of platelet...
Somatic Mutations and Co-Mutations Predict AML Risk in Women
According to results from a deep-sequencing analysis published in Nature Medicine, women with mutations of the TP53 and IDH genes in the absence of...
Age, Anthracycline Dose, Hypertension Contribute to Higher CVD Risk in HCT Recipients
In a study published in Blood Advances, investigators reviewed data from a large cohort of patients who had undergone a hematopoietic cell transplantation (HCT)...
September 2018 Issue
APR-246 Plus Azacitidine Is Associated With High Response Rates in MDS and AML
In a small phase IB/II trial presented at the 23rd Congress of the European Hematology Association, all four evaluable patients with TP53-mutant myelodysplastic syndromes...
Umbralisib Demonstrates Safety, Efficacy for Patients With Kinase Inhibitor–Intolerant CLL
According to a report presented at the 23rd Congress of the European Hematology Association, the phosphoinositide 3-kinase (PI3K) and casein kinase-1ε inhibitor umbralisib represents...
Tagraxofusp: A New Option for Blastic Plasmacytoid Dendritic Cell Neoplasm?
Treatment with tagraxofusp, an anti-CD123 targeted agent previously known as SL-401, appeared to be safe and effective for managing blastic plasmacytoid dendritic cell neoplasm...
